Compliance differences between patients with breast cancer in university and county hospitals

Clinical Breast Cancer

Volumn 10, Issue 5, 2010, Pages 385-391

  Komenaka, Ian ^a   Pennington, Robert ^a   Schneider, Bryan ^a   Hsu, Chiu Hsieh ^b   Norton, Laura ^a   Clare, Susan ^a   Zork, Noelia ^a   Goulet, Robert ^a  

^a INDIANA UNIVERSITY   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

Chemoprevention; Preoperative chemotherapy; Radiation therapy; Underinsured

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; PACLITAXEL;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; MULTIPLE CYCLE TREATMENT; PARTIAL MASTECTOMY; PATIENT COMPLIANCE; PREOPERATIVE TREATMENT; RETROSPECTIVE STUDY; TEACHING HOSPITAL; TUMOR VOLUME;

EID: 77957813926     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2010.n.051     Document Type: Article

References (40)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemo-therapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365:1687-717.
2. Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997; 15:2483-93.
3. Bear HD, Anderson S, Brown A, et al. The effect on tumor response of adding se-quential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from NSABP Protocol B-27. J Clin Oncol 2003; 21:4165-74.
4. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003; 21:976-83.
5. Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005; 352:2302-13.
6. Hand R, Sener S, Imperato J, et al. Hospital variables associated with quality of care for breast cancer patients. JAMA 1991; 266:3429-32.
7. Balasubramanian SP, Murrow S, Holt S, et al. Audit of compliance to adjuvant chemotherapy and radiotherapy guidelines in breast cancer in a cancer network. Breast 2003; 12:136-41.
8. Vinh-Hung V, Verschraegen C. Breast-conserving surgery with or without radio-therapy: pooled-analysis for risks of ipsilateral breast tumor recurrence and mortal-ity. J Natl Cancer Inst 2004; 96:115-21.
9. Fink AK, Gurwitz J, Rakowski W, et al. Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer. J Clin Oncol 2004; 22:3309-15.
10. Buchholz TA, Theriault RL, Niland JC, et al. The use of radiation as a component of breast conservation therapy in National Comprehensive Cancer Network Centers. J Clin Oncol 2006; 24:361-9.
11. Bickell NA, Wang JJ, Oluwole S, et al. Missed opportunities: racial disparities in adjuvant breast cancer treatment. J Clin Oncol 2006; 24:1357-62.
12. Landercasper J, Dietrich LL, Johnson JM. A breast center review of compliance with National Comprehensive Cancer Network Breast Cancer guidelines. Am J Surg 2006; 192:525-7.
13. Foley KL, Kimmick G, Camacho F, et al. Survival disadvantage among Medicaid-insured breast cancer patients treated with breast conserving surgery without radiation therapy. Breast Cancer Res Treat 2007; 101:207-14.
14. Kirk MC, Hudis CA. Insight into barriers against optimal adherence to oral hor-monal therapy in women with breast cancer. Clin Breast Cancer 2008; 8:155-61.
15. Partridge AH, LaFountain A, Mayer E, et al. Adherence to initial adjuvant anas-trozole therapy among women with early-stage breast cancer. J Clin Oncol 2008; 26:556-62.
16. Fisher B, Bauer M, Margolese R, et al. Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med 1985; 312:665-73.
17. Hughes KS, Schnaper LA, Berry D, et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med 2004; 351:971-7.
18. Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA 2004; 291:2720-6.
19. Gross CP, Filardo G, Mayne ST, et al. The impact of socio-economic status and race on trial participation for older women with breast cancer. Cancer 2005; 103:483-91.
20. American Hospital Directory [Web site]. Available at: http://www.ahd.com/. Accessed: June 25, 2010.
21. National Comprehensive Cancer Network [Web site]. Available at: http://www. nccn.org/. Accessed: June 25, 2010.
22. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006; 24:3726-34.
23. Albain KS, Green SR, Lichter AS, et al. Influence of patient characteristics, socioeconomic factors, geography, and systemic risk on the use of breast-sparing treatment in women enrolled in adjuvant breast cancer studies: an analysis of two intergroup trials. J Clin Oncol 1996; 14:3009-17.
24. Morrow M, Bucci C, Rademaker A. Medical contraindications are not a major factor in the underutilization of breast conserving therapy J Am Coll Surg 1998; 186: 269-74.
25. Desch CE, Penberthy LT, Hillner BE, et al. A sociodemographic and economic comparison of breast reconstruction, mastectomy, and conservative surgery. Surgery 1999; 125:441-7.
26. Lazovich D, Solomon CC, Thomas DB, et al. Breast conservation therapy in the United States following the 1990 National Institutes of Health Consensus Development Conference on the treatment of patients with early stage invasive breast carcinoma. Cancer 1999; 86:628-37.
27. Heimbach JK, Biffl WL, Mitchell EL, et al. Breast conservation therapy in affili-ated county, university, and private hospitals. Am J Surg 1999; 178:466-9.
28. Hiotis K, Ye W, Sposto R, et al. Predictors of breast conservation therapy: size is not all that matters. Cancer 2005; 103:892-9.
29. Dolan JT, Granchi TS, Miller CC III, et al. Low use of breast conservation surgery in medically indigent populations. Am J Surg 1999; 178:470-4.
30. Chagpar AB, Studts JL, Scoggins CR, et al. Factors associated with surgical options for breast carcinoma. Cancer 2006; 106:1462-6.
31. Zork NM, Komenaka IK, Pennington RE Jr, et al. The effect of dedicated breast surgeons on the short-term outcomes in breast cancer. Ann Surg 2008; 248:280-5.
32. Bland KI, Menck HR, Scott-Conner CE, et al. The National Cancer Data Base 10-year survey of breast carcinoma treatment at hospitals in the United States. Cancer 1998; 83:1262-73.
33. White J, Morrow M, Moughan J, et al. Compliance with breast-conservation standards for patients with early-stage breast carcinoma. Cancer 2003; 97:893-904.
34. Yen TW, Hunt KK, Mirza NQ, et al. Physician recommendations regarding tamoxifen and patient utilization of tamoxifen after surgery for ductal carcinoma in situ. Cancer 2004; 100:942-9.
35. Hird RB, Chang A, Cimmino V, et al. Impact of estrogen receptor expression and other clinicopathologic features on tamoxifen use in ductal carcinoma in situ. Cancer 2006; 106:2113-8.
36. Adjuvant! Online [Web site]. Available at: http://www.adjuvantonline.com. Accessed: June 25, 2010.
37. Eisinger F, Ronda I, Puig B, et al. Breast cancer guidelines-physicians' intentions and behaviors. Int J Cancer 2007; 120:1136-40.
38. Ma AM, Barone J, Wallis AE, et al. Noncompliance with adjuvant radiation, chemotherapy, or hormonal therapy in breast cancer patients. Am J Surg 2008; 196:500-4.
39. Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006; 355:1114-23.
40. Wolmark N, Wang J, Mamounas E, et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001; (30):96-102.